Cognitive impairment restoration in patients suffered with stroke during the post-COVID period
Keywordsstroke, mnestic dysfunctions, pathogenetic mechanisms of cerebral ischemia, post-COVID period, pharmacological correction, magnetic therapy
Frequency of vascular complications, including strokes, in patients suffered from COVID-19 infection is known to be increased up to 8 times, especially compared with influenza. The purpose: to investigate the fundamental mechanisms of brain ischemia in the patients with mnestic dysfunctions who previously underwent COVID-19 through pharmacocorrection via Phenibut (g-amino-b-phenylbutyric acid hydrochloride) and magnetic therapy in the early recovery period of ischemic stroke. The authors describe the possibilities of cognitive rehabilitation for people who have had ischemic stroke in the post-COVID period. Considering that the presence of mnestic dysfunctions has a negative impact on the process of rehabilitation of cerebral accidents, the fundamental mechanisms of brain ischemia in patients with mnestic dysfunctions in the early recovery period in patients who have undergone COVID-19 have been studied through pharmacocorrection via Phenibut (g-amino-b-phenylbutyric acid hydrochloride) and magnetic therapy. 46 patients aged 40 to 60 years were examined. A comparative study of three randomized clinical groups of patients with separate and complex use of Phenibut and magnetic stimulation. The effectiveness of the proposed therapy in restoring executive functions was established on the basis of indicators of the MMSE scale, the test for the study of frontal dysfunction – FAB, regression of depressive symptoms and is characterized by a decrease in the score on the GDS scale. The authors conclude that mnestic disorders are a functional "target" in cerebral ischemia in the post-COVID period, which requires close attention in relation to pharmacocorrection methods and comprehensive rehabilitation and further research, including the elucidate the pathogenetic mechanisms of cerebral ischemia.
Kispaeva TT. On the issue of cognitive rehabilitation of patients with acute cerebral stroke. Attending physician. 2010; 10: 70–72 [In Russian].
Prokopenko SV, Mozheiko EYu, Shvetsova IN. Recovery of cognitive functions after a stroke using stimulation of sensory areas of the brain. Doctor.Ru. 2017; 11(140): 13–18 [In Russian].
Pulik OR, Stoyanov OM, Giryavets MV, Vastyanov RS. Drug and non-drug correction of post-stroke cognitive impairment. Journal of Education, Health and Sport. 2015; 5(5): P.101-108 [In Ukrainian].
Skvortsova VI, Efremova NV, Shalamov NA. Cerebral cerebral ischemia. Medicine. 2006; 2(13): 35–40 [In Russian].
Stoyanov AN, Vastyanov RS, Kubareva DA, Bakumenko IK. The effectiveness of the use of noofen for the correction of autonomic dysfunctions in adolescents with cerebral angiodystonia and motor disorders. Ukrainian Bulletin of Psychoneurology. 2012; 20(4): 114-119[In Ukrainian].
Stoyanov AN. Possibilities of therapy of motor components of vegetative dysfunctions. Kiev. 2014: 28 [In Russian].
Stoyanov AN. Neurovegetative aspects of cardialgia menopause. Kiev. 2016: 76 [In Russian].
Bekelis K, Missios S, Ahmad J, et al. Ischemic stroke occurs less frequently in patients with COVID-19: a multicenter cross-sectional study. Stroke. 2020;51:3570-3576.
Chen X, Wang K. The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995—2015. Acta Pharm Sin B. 2016; 6(6): 522—530
Dries DJ, Hussein HM. Coronavirus Disease 2019 and Stroke. Air Med J. 2021; 40(2):92-96. doi:10.1016/j.amj.2020.12.003
Ellul MA, Benjamin L, Singh B. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783
Fifi JT, Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol. 2020;19:713-715.
Katsanos AH, Palaiodimou L, Zand R, Yaghi S, Kamel H, Navi BB, Turc G, Romoli M, Sharma VK, Mavridis D, Shahjouei S, Catanese L, Shoamanesh A, Vadikolias K, Tsioufis K, Lagiou P, Alexandrov AV, Tsiodras S, Tsivgoulis G. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis. Ann Neurol. 2021; 89(2): 380-388. doi: 10.1002/ana.25967.
Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471-481. doi:10.1111/j.1527-3458.2001.tb00211.x
Naeimi R, Ghasemi-Kasman M. Update on cerebrovascular manifestations of COVID-19. Neurol Sci. 2020;41:3423-3435
Natarelli L, Virgili F, Weber C. SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad. Int J Mol Sci. 2021 ; 22 (22): 12243. doi: 10.3390/ijms222212243.
Ostroumova TM, Chernousov PA, Kuznetsov IV. Cognitive impairment in COVID-19 survivors. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):126–130. DOI: 10.14412/2074-2711-2021-1-126-130
Оxley TJ, Mocco J, Majidi S., Kellner CP., Shoirah H, Singh P, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fifi JT. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020; 382(20): 60 doi: 10.1056/NEJMc2009787.
Paniz-Mondolfi A, Bryce C, Grimes Z. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702
del Ser T, Barba R, Morrin MM, DomingoJ, Cemillan C, Pondal M, Vivancos J. Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke. 2005; 36(12): 2670–2675. doi: 10.1161/01.STR.0000189626.71033.35
Varga Z, Flammer AJ, Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418.
Vastyanov R.S., Sadovyi O.S., Stoyanov O.M., Dobrovolskyi V.V., Vastyanova O.V., Gruzevskyi O.A. Cognitive disorders expression and their pathogenetic correction in the dynamics of streptozotocin-induced diabetes. World of Medicine and Biology. 2021; 4(78): 203-208. doi 10.26724/2079-8334-2021-4-78-203-208
How to Cite
Copyright (c) 2022 O. Stoyanov, A. Son, R. Vastyanov, N. Turchin, O. Gruzevsky, P. Yermuraki, O. Dzygal, M. Vastyanov
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 146
Number of citations: 0